Lv1
78 积分 2025-04-21 加入
Efficacy and safety of interventions for metastatic castration resistant prostate cancer (mCRPC) patients progressing on androgen receptor-axis-targeted (ARAT) therapy: a systematic literature review
28天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
Development of RMC-6236, a potent and orally bioavailable RAS(ON) multi-selective tri-complex inhibitor for the treatment of RAS-addicted cancers by targeting multiple RAS variants
2个月前
已关闭
Remodeling cyclophilin A to target KRAS
2个月前
已完结
Unique features of trabectedin mechanism of action
7个月前
已完结
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
7个月前
已完结
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
8个月前
已完结
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
9个月前
已完结
Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer
9个月前
已完结
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers
9个月前
已完结
皖公网安备34019202002308
